Dr. Chevalier received his Ph.D. in structural biology and nanobiology from the University Joseph Fourier, Grenoble, France. He integrated the thrombosis and angiogenesis and drug design departments at Sanofi, Toulouse, France where he has been involved in hit to lead and lead optimization for several projects in cardiovascular disease and oncology. He moved then to Barcelona, Spain and participated actively to the development of former start-up Crystax (now wholly owned subsidiary of Oryzon genomics) as project manager for CNS and cancer drug research. He specialized in fragment based drug discovery using innovative combination of biophysical technique (NMR, Crystallography), computational methods (docking, molecular dynamics, predictive metabolic stability and toxicological properties) and in vitro assay (binding and enzymatic) to enhance hit discovery and reduce time needed to develop leads. He decided to create his own start-up, ECSIMTECH-biosciences, a platform for B2B and B2C in Drug discovery and development. He also obtained a MBA in Business Management during the same period. He served tebu-bio as territory sales and technical support for target based assay, screening, ADME/Toxicology products and services, including drug metabolism, drug induced toxicity, hepatotoxicity, and cardiotoxicity. He was in charge of training given to metabolism and pharmacokinetics departments of pharmaceuticals companies in Southern Europe. He recently joined Acellera Ltd, Barcelona, Spain, as business and scientific developer. "His main duties are the development of the business activity, management of the different departments (sales, marketing, operation and R D) and supervise R D team to match market needs". He has more than 15 years' experience in life sciences, with proven track record, especially in drug discovery and development, most of it acquired in industrial environment.
Drug Discovery and Development; Drug Design; Drug metabolism; ADME; Toxicology; Predictive ligand-target interactions; Fragment based Drug Discovery; Computational Chemistry; Theoretical Pharmacology.